依达拉奉治疗老年急性脑梗死的临床疗效

目的评价依达拉奉治疗急性老年脑梗死的临床疗效和安全性。方法将226例老年急性脑梗死患者分为依达拉奉治疗组(治疗组)115例和常规治疗组(对照组)111例,在治疗前及治疗后第7、14和21天进行欧洲卒中评分(ESS)判断治疗效果。结果共220例完成临床观察,治疗组114例,死亡1例,死于心功能衰竭;对照组106例,死亡5例,4例死于大片脑梗死、脑疝形成,1例脑干梗死者死于中枢性呼吸功能衰竭。治疗组的ESS增分率自第7天开始,治疗组第14和21天的ESS有效率分别为50．0％和62．3％,对照组分别为26．4％和34．0％,两组的差异均有统计学意义(P值均<0．01)。结论依达拉奉治疗急性老年脑梗死安全、有效。

Evaluation of edaravone injection in treatment of acute senile cerebral infarction

Objective To evaluate the efficacy and safety of Edaravone on veteran patients with acute senile cerebral infarction. Methods Two hundred and twenty-six cases of acute senile cerebral infarction were randomized into Edaravone group (115 cases) and control group (111 cases). European stroke scale (ESS) was conducted to evaluate the efficacy of both groups before the therapy and 7d, 14 d, 21 d after initiation of the therapy. Results Two hundred and twenty cases including 114 cases of Edaravone group and 106 cases of the control group completed the clinical trial. One case of Edaravone group died of heart failure and 4 cases of the control group died of massive cerebral infarction with hernia formation and 1 died of respiratory center failure due to brain stem infarction. ESS efficacy rates of Edaravone group started to increase at 7 d after initiation of therapy and reached 50. 0% and 62. 3% at 14 d and 21 d whereas those of the control group were 26. 4% and 34. 0% respectively (P < 0. 01), showing statistically significant difference. Conclusion Edaravone therapy has been proven efficacious and safe in treating acute senile cerebral infarction.